📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
520 announcements match the current filters (relevance ≥ 5).
CARE Ratings Reports Strong FY26 Performance with 24% PAT Growth and Rs. 14 Final Dividend
CARE Ratings delivered a robust performance for FY26, with consolidated revenue growing 18% YoY to Rs. 473.07 crore and PAT increasing 24% YoY to Rs. 173.69 crore. The company maintained strong profitability, with consolidated EBITDA margins expanding to 42% for the full year. A final dividend of Rs. 14 per share has been recommended, bringing the total dividend for FY26 to Rs. 22 per share. Growth was well-distributed, with the core ratings segment growing 17% and the non-ratings segment increasing by 19%.
Key Highlights
Consolidated PAT for FY26 rose 24% YoY to Rs. 173.69 crore, marking an all-time high.
Consolidated Revenue from Operations increased 18% YoY to Rs. 473.07 crore in FY26.
Recommended a final dividend of Rs. 14 per share, resulting in a total annual dividend of Rs. 22.
Consolidated EBITDA grew by 27% YoY to Rs. 197.39 crore with a margin of 42%.
Non-ratings segment revenue grew by 19% YoY to Rs. 50.01 crore, contributing 11% to total revenue.
👀 What to Watch
Investors should take note of the significant margin expansion and the company's successful diversification into non-rating segments. The high dividend yield and strong cash flow generation make it an attractive pick for long-term portfolios.
CARE Ratings Recommends ₹14 Dividend and Reports Audited FY26 Results
CARE Ratings has announced a final dividend of ₹14 per share for the financial year 2026, with the record date fixed for June 26, 2026. The Board approved the audited financial results for FY26 with an unmodified opinion from auditors B S R & Co. LLP. The company also granted 55,000 ESOPs at an exercise price of ₹1,590 per share. Furthermore, the management provided an update on the pending stake sale of its IFSC subsidiary to SBI and NSE IFSC, noting that legal documentation is taking longer than expected.
Key Highlights
Recommended a final dividend of ₹14 per equity share for FY26, with a record date of June 26, 2026.
Granted 55,000 stock options to eligible employees at an exercise price of ₹1,590 per share.
Re-appointed B S R & Co. LLP as Statutory Auditors for a five-year term ending in 2031.
Reported delays in the partial stake sale of CareEdge Global IFSC Limited to SBI and NSE IFSC due to prolonged legal discussions.
The 33rd Annual General Meeting (AGM) is scheduled for July 3, 2026, via video conferencing.
👀 What to Watch
Investors should benefit from the healthy ₹14 dividend payout and should monitor the eventual completion of the IFSC subsidiary stake sale to marquee partners like SBI.
CARE Ratings Recommends ₹14 Final Dividend and Re-appoints Statutory Auditors
CARE Ratings has recommended a final dividend of ₹14 per equity share for the financial year 2026, with the record date set for June 26, 2026. The company also approved the re-appointment of B S R & Co. LLP as statutory auditors for a five-year term until 2031. Additionally, 55,000 stock options were granted to employees at an exercise price of ₹1,590 per share. The company reported a delay in the partial stake sale of its subsidiary, CareEdge Global IFSC Limited, to SBI and NSE IFSC due to ongoing legal documentation.
Key Highlights
Recommended a final dividend of ₹14 per equity share (Face Value ₹10) for FY26.
Re-appointed B S R & Co. LLP as Statutory Auditors for a 5-year term (2026-2031).
Granted 55,000 ESOPs under the 2020 scheme at an exercise price of ₹1,590.
Partial stake sale of CareEdge Global IFSC to SBI and NSE IFSC is still under negotiation due to documentation delays.
👀 What to Watch
Investors should ensure they hold shares by the June 26 record date to qualify for the ₹14 dividend. Monitor the eventual closure of the subsidiary stake sale to SBI and NSE IFSC as a potential catalyst for the stock.
CARE Ratings Declares ₹14 Dividend and Grants 55,000 ESOPs at ₹1,590 Exercise Price
CARE Ratings has recommended a final dividend of ₹14 per share for FY26, with the record date set for June 26, 2026. The company also approved the grant of 55,000 stock options to employees at an exercise price of ₹1,590 per share, vesting over three years. Additionally, the board provided an update on the delayed partial stake sale of its subsidiary, CareEdge Global IFSC Limited, to SBI and NSE IFSC, confirming that negotiations are still active. B S R & Co. LLP has been re-appointed as the statutory auditor for a five-year term.
Key Highlights
Recommended a final dividend of ₹14 per equity share (Face Value ₹10) for FY26.
Granted 55,000 stock options under the 2020 ESOP scheme at an exercise price of ₹1,590.
Set June 26, 2026, as the record date for dividend eligibility.
Re-appointed B S R & Co. LLP as Statutory Auditors for a five-year term until 2031.
Confirmed ongoing negotiations for the stake sale in CareEdge Global IFSC Limited to SBI and NSE IFSC.
👀 What to Watch
Investors should note the ₹14 dividend and the June 26 record date for eligibility. Monitor the eventual closure of the subsidiary stake sale to SBI and NSE as a potential valuation catalyst.
CARE Ratings Recommends ₹14 Final Dividend; Sets June 26 as Record Date
CARE Ratings has announced a final dividend of ₹14 per share for the financial year 2026, subject to shareholder approval at the upcoming AGM. The company has fixed June 26, 2026, as the record date for determining eligibility for this payout. In addition to the dividend, the board approved the grant of 55,000 stock options at an exercise price of ₹1,590. Investors should also note that the proposed partial stake sale of its subsidiary, CareEdge Global IFSC Limited, to SBI and NSE IFSC is experiencing delays due to prolonged legal negotiations.
Key Highlights
Recommended a final dividend of ₹14 per equity share (140% of face value) for FY26.
Fixed June 26, 2026, as the record date for the dividend payment.
Approved the grant of 55,000 stock options under the 2020 ESOP scheme at an exercise price of ₹1,590.
Re-appointed B S R & Co. LLP as Statutory Auditors for a five-year term until 2031.
Reported that negotiations for the stake sale in CareEdge Global IFSC Limited to SBI and NSE IFSC are ongoing but delayed.
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the June 26 record date. Monitor the progress of the subsidiary stake sale as it remains a key corporate development for value unlocking.
CARE Ratings Recommends ₹14 Final Dividend and Reports FY26 Results; Subsidiary Stake Sale Delayed
CARE Ratings has recommended a final dividend of ₹14 per share for FY26, following the approval of its annual audited financial results. The company has set June 26, 2026, as the record date for the dividend payment, which is subject to shareholder approval at the AGM on July 3, 2026. The board also approved the grant of 55,000 ESOPs at an exercise price of ₹1,590 per share. However, the company noted a delay in the partial stake sale of its subsidiary, CareEdge Global IFSC Limited, to SBI and NSE IFSC due to ongoing legal negotiations.
Key Highlights
Recommended a final dividend of ₹14 per equity share for the financial year ended March 31, 2026.
Set June 26, 2026, as the record date for dividend eligibility.
Approved the grant of 55,000 stock options under the 2020 ESOP scheme at an exercise price of ₹1,590.
Reported a delay in the partial stake sale of subsidiary CareEdge Global IFSC Limited to SBI and NSE IFSC.
Re-appointed B S R & Co. LLP as statutory auditors for a five-year term until 2031.
👀 What to Watch
Investors should track the record date of June 26 to qualify for the ₹14 dividend and monitor updates regarding the strategic stake sale to SBI and NSE.
CARE Ratings Recommends ₹14 Final Dividend; Delays Stake Sale in Subsidiary
CARE Ratings has recommended a final dividend of ₹14 per equity share for the financial year ended March 31, 2026. The company has set June 26, 2026, as the record date for the dividend, which is subject to shareholder approval at the upcoming AGM on July 3, 2026. Additionally, the board approved the grant of 55,000 ESOPs at an exercise price of ₹1,590 per share. Investors should note that the proposed partial stake sale of its subsidiary, CareEdge Global IFSC Limited, to SBI and NSE IFSC has been delayed due to prolonged legal negotiations.
Key Highlights
Recommended a final dividend of ₹14 per equity share of face value ₹10 each.
Record date for dividend payment fixed as June 26, 2026.
Approved grant of 55,000 stock options to employees at an exercise price of ₹1,590.
Re-appointed B S R & Co. LLP as statutory auditors for a five-year term until 2031.
Reported a delay in the partial stake sale of CareEdge Global IFSC Limited to SBI and NSE IFSC.
👀 What to Watch
Investors may consider holding the stock to benefit from the ₹14 dividend payout while monitoring the eventual completion of the subsidiary stake sale to SBI and NSE.
Religare FY26 Revenue Hits ₹8,494 Cr; Care Health GWP Grows 24% to ₹11,417 Cr
Religare Enterprises Limited (REL) reported a consolidated revenue of ₹8,494 crore for FY26, primarily driven by its health insurance subsidiary, Care Health, which saw a 24% YoY growth in Gross Written Premium (GWP) to ₹11,417 crore. The NBFC arm, Religare Finvest (RFL), turned profitable with a PAT of ₹138.8 crore for the full year, significantly improving its CRAR to 261.9% and reducing NNPA to 0.8%. The company is also progressing with a strategic demerger to separate its insurance and financial services businesses and has announced a ₹1,500 crore capital raise via convertible warrants.
Key Highlights
Consolidated FY26 revenue reached ₹8,494 Cr, led by Care Health Insurance's GWP of ₹11,417 Cr.
Religare Finvest (RFL) reported a PAT of ₹138.8 Cr in FY26 compared to ₹24 Cr in FY25, with NNPA at a low 0.8%.
Care Health Insurance maintained a 22% market share in the SAHI segment with a claim settlement ratio exceeding 97%.
The Burman Group was designated as Promoters in Feb 2025, currently holding a ~30.3% stake.
Board approved a demerger of the Financial Services business to Religare Finvest Limited for sharper segment focus.
👀 What to Watch
Investors should view the turnaround in the NBFC business and the sustained growth in the health insurance segment as positive indicators. Monitor the upcoming demerger process and the utilization of the ₹1,500 crore capital raise for future expansion.
Religare FY26 Revenue Grows 14.7% to ₹8,494 Cr; Health Insurance GWP Up 24%
Religare Enterprises reported a 14.7% YoY growth in consolidated revenue to ₹8,493.84 crore for FY26, driven largely by the health insurance segment. However, consolidated PAT saw a significant decline to ₹73.16 crore from ₹182.75 crore in FY25. The health insurance business (Care Health) remains the primary growth engine, with Gross Written Premium reaching ₹11,417 crore and a 19.7% market share in the SAHI category. Strategic highlights include a ₹1,500 crore capital raise from the Burman family and the removal of RBI's Corrective Action Plan for the NBFC arm, Religare Finvest.
Key Highlights
Consolidated Revenue increased 14.7% YoY to ₹8,493.84 crore in FY26.
Health Insurance GWP grew 24% to ₹11,417 crore with profitability improving 38% to ₹539 crore.
Religare Finvest (RFL) is now debt-free with a net worth of ₹898.8 crore following RBI CAP removal.
Raised ₹1,500 crore via preferential allotment of convertible warrants to the Burman family and others.
Consolidated PAT for FY26 stood at ₹73.16 crore, down from ₹182.75 crore in the previous fiscal year.
👀 What to Watch
Investors should monitor the scaling of the NBFC business now that regulatory restrictions are lifted and track the progress of the planned demerger. While revenue growth is healthy, the decline in consolidated PAT suggests higher operational or transition costs that need to be evaluated in upcoming quarters.
Religare Enterprises Reports FY26 Standalone Net Loss of ₹33.80 Crore; Revenue Drops 60.7%
Religare Enterprises Limited reported a standalone net loss of ₹33.80 crore for the fiscal year ended March 31, 2026, a slight improvement from the ₹37.54 crore loss in the previous year. However, total income witnessed a significant decline of 60.7%, falling to ₹16.44 crore from ₹41.82 crore in FY25. While the company managed to reduce total expenses by 39.3% to ₹50.36 crore, it remains in a loss-making position. Investors should also note the auditor's emphasis on ongoing income tax litigations and related tax demands.
Key Highlights
Annual standalone total income fell sharply to ₹16.44 crore in FY26 from ₹41.82 crore in FY25.
Net loss for the full year narrowed slightly to ₹33.80 crore compared to ₹37.54 crore in the previous fiscal.
Q4 FY26 standalone net loss stood at ₹12.36 crore versus a loss of ₹17.74 crore in Q4 FY25.
Total annual expenses were reduced to ₹50.36 crore from ₹82.94 crore in the prior year.
Statutory auditors issued an unmodified opinion but included an 'Emphasis of Matter' regarding ongoing income tax litigations.
👀 What to Watch
The company's standalone performance remains weak with a significant drop in revenue and persistent losses. Investors should exercise caution and closely monitor the resolution of tax litigations and the performance of its key subsidiaries in the consolidated report.
RS Software Approves FY26 Audited Financial Results; Receives Unmodified Audit Opinion
R. S. Software (India) Limited has officially approved its audited standalone and consolidated financial results for the quarter and full financial year ending March 31, 2026. The company confirmed that the statutory auditors have issued an unmodified opinion, suggesting no significant accounting discrepancies or qualifications. Furthermore, the company clarified that it does not qualify as a 'Large Corporate' under SEBI's debt issuance framework, meaning it is not mandated to raise incremental borrowings through debt securities. This announcement serves as a procedural confirmation of the company's financial reporting integrity for the fiscal year.
Key Highlights
Board approved audited standalone and consolidated results for the financial year ending March 31, 2026.
Statutory auditors issued an Unmodified Opinion on the financial results for the period.
Company confirmed it does not meet the SEBI criteria for 'Large Corporate' status as of April 02, 2026.
The Board meeting for result approval concluded at 1:50 PM on May 07, 2026.
Q4 results were derived by subtracting nine-month figures from the full-year audited totals as per SEBI regulations.
👀 What to Watch
Investors should review the detailed financial tables once available to evaluate specific revenue and margin trends, though the clean audit report is a positive sign of transparency. The non-applicability of the Large Corporate framework indicates the company's debt levels or market capitalization remain below the SEBI-defined thresholds.
Bajaj Healthcare FY26 Revenue Up 12.6% to ₹611 Cr; Net Profit Drops 60% on Exceptional Loss
Bajaj Healthcare reported a 12.6% YoY growth in annual revenue to ₹61,103 Lakhs for FY26. However, the company faced a significant net loss of ₹2,285 Lakhs in Q4 FY26, primarily due to a one-time exceptional item of ₹3,324 Lakhs related to a technical know-how income reversal from a Middle East contract. Annual net profit consequently declined by 60% to ₹1,576 Lakhs. Despite the profit hit, the board recommended a final dividend of ₹1.50 per share and successfully utilized ₹15,000 Lakhs from warrant conversions for debt repayment.
Key Highlights
Annual Revenue from continuing operations grew 12.6% YoY to ₹61,103.14 Lakhs.
Q4 FY26 reported a net loss of ₹2,285.06 Lakhs vs a profit of ₹1,117.78 Lakhs in the previous year's quarter.
Exceptional loss of ₹3,324.66 Lakhs recognized in Q4 due to reversal of income from a technical know-how arrangement.
Board recommended a final dividend of 30% (₹1.50 per equity share) for FY 2025-26.
Company utilized ₹15,000 Lakhs from preferential issue proceeds for loan repayment, significantly reducing debt.
👀 What to Watch
Investors should monitor the company's ability to stabilize margins following the one-time income reversal and the progress of the Genrx Pharmaceuticals acquisition. While the debt reduction is a positive structural change, the volatility in contract-based income suggests a need for caution.
Bajaj Healthcare FY26 PAT Rises 27% to ₹545.6 Mn; API Exports Surge 51.6%
Bajaj Healthcare reported a 12.6% YoY revenue growth for FY26, reaching ₹6,110.3 Mn, driven primarily by a robust 51.6% surge in API exports. While Q4 revenue was flat due to domestic API price erosion, PAT from continuing operations grew 19.3% in Q4 and 27.1% for the full year. The company strengthened its balance sheet by raising ₹527 Mn through warrant conversion and expanded its pipeline with 41 new DMF filings in Q4. However, a one-time reversal of income from a Middle East contract due to regional instability impacted the final reported profit.
Key Highlights
FY26 Revenue grew 12.6% to ₹6,110.3 Mn, with API exports jumping 51.6% to ₹1,881.4 Mn.
PAT from continuing operations (before exceptional items) increased 27.1% YoY to ₹545.6 Mn in FY26.
Company filed 41 DMFs in Q4 FY26, bringing the cumulative total to 110 to target regulated markets.
Raised ₹527 Mn through the conversion of 2,079,409 warrants into equity shares to support growth.
Cenobamate (anti-epileptic) is on track for a Q2 FY27 launch following Phase III trials.
👀 What to Watch
Investors should monitor the successful launch of Cenobamate in Q2 FY27 and the scaling of the CDMO segment as key growth drivers. The strong export momentum and regulatory filings suggest a positive shift towards higher-margin regulated markets.
Bajaj Healthcare FY26 Revenue Grows 12.6% to ₹611 Cr; Net Profit Falls 60% on Exceptional Item
Bajaj Healthcare reported a 12.6% year-on-year growth in annual revenue to ₹61,103.14 Lakhs for FY26. However, Net Profit for the year declined sharply to ₹1,576.61 Lakhs from ₹3,949.55 Lakhs in FY25, primarily due to a one-time exceptional charge of ₹3,324.66 Lakhs involving the reversal of technical know-how income. The company reported a net loss of ₹2,285.06 Lakhs in Q4 FY26. Despite the profit decline, the board has recommended a final dividend of ₹1.50 per share (30% of face value).
Key Highlights
Annual Revenue from operations increased to ₹61,103.14 Lakhs in FY26 vs ₹54,260.24 Lakhs in FY25.
Net Profit for FY26 dropped 60% YoY to ₹1,576.61 Lakhs, impacted by a ₹3,324.66 Lakhs exceptional income reversal due to Middle East instability.
Q4 FY26 recorded a net loss of ₹2,285.06 Lakhs compared to a profit of ₹1,117.78 Lakhs in the same quarter last year.
Recommended a final dividend of ₹1.50 per equity share (30% of Face Value of ₹5).
Raised ₹17,300.18 Lakhs through preferential issues and warrant conversions, with ₹15,000 Lakhs utilized for loan repayment.
👀 What to Watch
Investors should treat the Q4 loss as largely driven by a one-time accounting reversal, but must monitor if geopolitical issues continue to hinder technical know-how exports. The significant reduction in debt through warrant conversion is a positive long-term development for the balance sheet.
Bajaj Healthcare Reports FY26 Revenue Growth of 12.6%; Recommends Rs 1.50 Dividend
Bajaj Healthcare reported a 12.6% YoY increase in FY26 revenue to Rs. 611.03 crore, though net profit fell significantly to Rs. 15.77 crore from Rs. 39.50 crore in FY25. The Q4 performance was severely impacted by a one-time exceptional loss of Rs. 33.25 crore due to the reversal of technical know-how income linked to Middle East instability. Despite a Q4 net loss of Rs. 22.85 crore, the board recommended a final dividend of Rs. 1.50 per share. The company also strengthened its capital base by raising Rs. 52.71 crore through warrant conversions.
Key Highlights
FY26 Revenue from operations increased to Rs. 61,103.14 lakhs from Rs. 54,260.24 lakhs in FY25.
Reported a significant exceptional item of Rs. 3,324.66 lakhs in Q4 FY26 due to income reversal.
Total Net Profit for FY26 dropped to Rs. 1,576.61 lakhs compared to Rs. 3,949.55 lakhs in the previous year.
Recommended a final dividend of Rs. 1.50 per equity share (30% of face value of Rs. 5).
Raised Rs. 5,271.30 lakhs through the conversion of 20,79,409 warrants into equity shares for debt repayment and CAPEX.
👀 What to Watch
Investors should exercise caution as the sharp decline in profitability and the large income reversal indicate high sensitivity to geopolitical risks. Monitor the successful integration of the Genrx acquisition and the impact of debt repayment on future margins.
Bajaj Healthcare FY26 Revenue Up 12.6%; Q4 Hit by ₹33.2 Cr Exceptional Loss
Bajaj Healthcare reported a 12.6% YoY growth in annual revenue to ₹611.03 crore for FY26. However, annual net profit declined sharply to ₹15.77 crore from ₹39.50 crore in the previous year, primarily due to a significant exceptional item in Q4. The company reversed ₹33.25 crore of income related to a technical know-how transfer due to regional instability in the Middle East. Despite the quarterly loss of ₹22.85 crore, the board has recommended a final dividend of ₹1.50 per share.
Key Highlights
Annual revenue from operations increased to ₹611.03 crore in FY26 from ₹542.60 crore in FY25.
Q4 FY26 recorded a net loss of ₹22.85 crore compared to a profit of ₹11.18 crore in Q4 FY25.
Exceptional loss of ₹33.25 crore due to reversal of technical know-how income from a Middle East customer.
Company successfully raised ₹204.97 crore through warrants, utilizing ₹150 crore for debt repayment.
Board recommended a final dividend of 30% (₹1.50 per equity share of face value ₹5).
👀 What to Watch
Investors should be cautious regarding the volatility in earnings caused by geopolitical issues, though the substantial debt repayment of ₹150 crore strengthens the balance sheet. Monitor the NCLT approval for the Genrx Pharmaceuticals acquisition as a potential future growth driver.
Religare Subsidiary RHDFCL Appoints Pankaj Rathi as Executive Director and CFO
Religare Enterprises' step-down subsidiary, Religare Housing Development Finance Corporation Limited (RHDFCL), has appointed Mr. Pankaj Rathi as Executive Director and CFO effective April 06, 2026. Mr. Rathi brings over 15 years of experience in the BFSI sector, specifically in financial reporting, fundraising, and M&A. He previously served as CFO at Grihum Housing Finance, where he successfully raised over $1.3 billion in capital. This appointment is expected to strengthen the strategic and financial leadership of Religare's housing finance business.
Key Highlights
Mr. Pankaj Rathi appointed as Additional Director and Whole-Time Director (ED & CFO) of RHDFCL.
Appointee has over 15 years of experience and previously raised $1.3 billion in capital over 5 years.
Track record includes orchestrating a credit rating migration from AA- to AAA in a previous role.
Appointment is subject to the approval of shareholders of the subsidiary company.
👀 What to Watch
Investors should monitor if this leadership change leads to improved credit ratings and lower borrowing costs for the housing finance subsidiary. The appointee's strong track record in fundraising and M&A is a positive sign for the company's growth trajectory.
Religare Finvest Appoints Srinivasan Karthik as CEO and Managing Director
Religare Enterprises Limited's material subsidiary, Religare Finvest Limited (RFL), has appointed Mr. Srinivasan Karthik as its Chief Executive Officer and Key Managerial Personnel effective May 05, 2026. Mr. Karthik brings over 30 years of extensive experience, including a 10-year tenure at HDB Financial Services where he scaled consumer and asset finance portfolios. His further designation as Managing Director is currently pending approval from the Reserve Bank of India (RBI) and shareholders. This appointment is a strategic move to strengthen the leadership at RFL, leveraging his expertise in digital transformation and financial services.
Key Highlights
Mr. Srinivasan Karthik appointed as CEO of Religare Finvest Limited effective May 05, 2026
Brings 30+ years of experience in financial services, consumer financing, and asset financing
Previously spent a decade at HDB Financial Services building large-scale loan portfolios
Educational credentials include a B.Tech from IIT Delhi and a PGDM from IIM Bangalore
Designation as Managing Director is subject to upcoming RBI and shareholder approvals
👀 What to Watch
Investors should monitor the regulatory approval process for the Managing Director role as it signals stability in the subsidiary's leadership. The appointment of a high-pedigree professional from a major NBFC like HDB Financial is a positive indicator for RFL's future growth and digital strategy.
Waaree Energies FY26 PAT Doubles to ₹3,884 Cr; Order Book Reaches ₹53,000 Cr
Waaree Energies delivered a record-breaking FY26 performance with revenue growing 84% YoY to INR 26,537 crores and PAT doubling to INR 3,884 crores. The company surpassed its EBITDA guidance, achieving INR 6,617 crores, supported by a robust module production of 12.6 GW. With a massive order book of INR 53,000 crores and a planned capex of INR 30,000 crores, the company is aggressively pursuing vertical integration into glass, ingots, and wafers. The retail segment also showed strong momentum, contributing INR 5,515 crores to the total revenue.
Key Highlights
Revenue from operations grew 84% YoY to INR 26,537 crores with an operating EBITDA margin of 22.27%
Order book stands robust at approximately INR 53,000 crores, providing strong multi-year revenue visibility
Total module manufacturing capacity reached 26 GW, making it the largest non-Chinese manufacturer globally
Strategic acquisition of 55% stake in Associated Power Structures for INR 1,225 crores to enter the T&D segment
Planned capex of INR 30,000 crores for backward integration including a 10 GW ingot wafer facility in Nagpur
👀 What to Watch
Investors should focus on the company's successful transition toward a fully integrated energy player and its ability to surpass financial guidance. The aggressive backward integration and expansion into the US market are key long-term growth drivers to monitor.
Thyrocare Declares ₹7 Final Dividend and ₹5.5 Cr Investment in Subsidiary
Thyrocare's board has recommended a final dividend of ₹7.00 per share, bringing the total dividend for FY26 to ₹9.33 per share post-bonus adjustment. The company is investing up to ₹5.50 crore in its wholly-owned subsidiary, Think Health Diagnostics, to bolster its diagnostic capabilities. Leadership remains stable with the re-appointment of Rahul Franklin Guha as MD & CEO for a five-year term. Furthermore, the company is broadening its business scope via MOA amendments to include digital healthcare platforms and allied services.
Key Highlights
Recommended a final dividend of ₹7.00 per equity share for FY 2025-26.
Total FY26 dividend stands at ₹9.33 per share post-bonus adjustment.
Approved equity infusion of up to ₹5.50 crore in Think Health Diagnostics Private Limited.
Re-appointed Rahul Franklin Guha as MD & CEO for a 5-year term starting May 2027.
Proposed MOA alteration to expand business into digital platforms and broader healthcare services.
👀 What to Watch
Investors should take note of the consistent dividend payout and leadership continuity as positive indicators of corporate health. The strategic expansion into digital diagnostic platforms and allied services suggests a long-term growth roadmap beyond traditional pathology.
